COL2A1_HUMAN,T59N,0.378,-,-,-
COL2A1_HUMAN,T61N,0.312,-,-,-
COL2A1_HUMAN,I67V,0.205,-,-,-
COL2A1_HUMAN,I68H,0.592,Altered Metal binding (Pr = 0.37 | P = 9.8e-03); Gain of Disulfide linkage at C64 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02); Loss of Proteolytic cleavage at D65 (Pr = 0.11 | P = 0.04), ELME000007|PS01208,-
COL2A1_HUMAN,V72S,0.204,-,-,-
COL2A1_HUMAN,V72T,0.130,-,-,-
COL2A1_HUMAN,S77H,0.215,-,-,-
COL2A1_HUMAN,A94S,0.158,-,-,-
COL2A1_HUMAN,A94T,0.148,-,-,-
COL2A1_HUMAN,A96T,0.212,-,-,-
COL2A1_HUMAN,Q99P,0.471,-,-,-
COL2A1_HUMAN,Q99R,0.193,-,-,-
COL2A1_HUMAN,P100H,0.495,-,-,-
COL2A1_HUMAN,G101F,0.906,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Gain of Acetylation at K103 (Pr = 0.31 | P = 3.4e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of O-linked glycosylation at S97 (Pr = 0.19 | P = 0.02); Loss of Methylation at K106 (Pr = 0.18 | P = 0.01); Loss of Proteolytic cleavage at A96 (Pr = 0.16 | P = 7.5e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G101T,0.896,Gain of O-linked glycosylation at G101 (Pr = 0.34 | P = 3.8e-03); Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of Phosphorylation at G101 (Pr = 0.25 | P = 0.03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at A96 (Pr = 0.17 | P = 6.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000136|ELME000159|ELME000358|PS00005,-
COL2A1_HUMAN,G104T,0.945,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of O-linked glycosylation at G104 (Pr = 0.13 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000202|PS00005,-
COL2A1_HUMAN,P109W,0.893,Altered Disordered interface (Pr = 0.42 | P = 3.2e-03); Loss of B-factor (Pr = 0.30 | P = 8.4e-03); Loss of Acetylation at K113 (Pr = 0.28 | P = 5.7e-03); Loss of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K113 (Pr = 0.21 | P = 5.0e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.16 | P = 8.7e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,D111L,0.770,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K113 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 7.9e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,D114Q,0.688,Loss of Acetylation at K113 (Pr = 0.31 | P = 3.8e-03); Gain of Methylation at K119 (Pr = 0.21 | P = 3.9e-03); Loss of SUMOylation at K113 (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,K119R,0.185,-,-,-
COL2A1_HUMAN,A145P,0.238,-,-,-
COL2A1_HUMAN,A145T,0.104,-,-,-
COL2A1_HUMAN,P146S,0.536,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K143 (Pr = 0.25 | P = 0.01); Loss of Methylation at K143 (Pr = 0.25 | P = 2.1e-03); Loss of SUMOylation at K143 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K143 (Pr = 0.15 | P = 0.04), ELME000085,-
COL2A1_HUMAN,N160L,0.763,Loss of B-factor (Pr = 0.31 | P = 6.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000052|ELME000057|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,P169H,0.759,Loss of B-factor (Pr = 0.34 | P = 1.5e-03); Gain of Loop (Pr = 0.29 | P = 0.01), ELME000155,-
COL2A1_HUMAN,P169R,0.796,Loss of B-factor (Pr = 0.34 | P = 2.0e-03); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of ADP-ribosylation at P169 (Pr = 0.20 | P = 0.03); Gain of Methylation at P169 (Pr = 0.11 | P = 0.03), ELME000006|ELME000097|ELME000155,-
COL2A1_HUMAN,G171F,0.947,Altered Disordered interface (Pr = 0.42 | P = 3.1e-03); Loss of B-factor (Pr = 0.38 | P = 2.1e-04); Gain of Loop (Pr = 0.30 | P = 5.4e-03), ELME000155,-
COL2A1_HUMAN,G176S,0.599,Gain of Loop (Pr = 0.31 | P = 3.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at G176 (Pr = 0.19 | P = 0.02), ELME000085|ELME000197|PS00008,-
COL2A1_HUMAN,D188E,0.275,-,-,-
COL2A1_HUMAN,E189D,0.359,-,-,-
COL2A1_HUMAN,S236A,0.142,-,-,-
COL2A1_HUMAN,P305T,0.390,-,-,-
COL2A1_HUMAN,S313A,0.181,-,-,-
COL2A1_HUMAN,P314A,0.253,-,-,-
COL2A1_HUMAN,S319A,0.224,-,-,-
COL2A1_HUMAN,G360S,0.917,Gain of Loop (Pr = 0.32 | P = 1.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000136|ELME000159,-
COL2A1_HUMAN,A404V,0.313,-,-,-
COL2A1_HUMAN,T412A,0.246,-,-,-
COL2A1_HUMAN,A418P,0.862,Gain of B-factor (Pr = 0.27 | P = 0.01); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Methylation at K419 (Pr = 0.26 | P = 1.5e-03); Loss of Ubiquitylation at K419 (Pr = 0.22 | P = 2.7e-03); Loss of SUMOylation at K419 (Pr = 0.19 | P = 0.04), ELME000239|PS00008,-
COL2A1_HUMAN,A476T,0.152,-,-,-
COL2A1_HUMAN,A493G,0.301,-,-,-
COL2A1_HUMAN,I503A,0.259,-,-,-
COL2A1_HUMAN,A539T,0.213,-,-,-
COL2A1_HUMAN,P548T,0.692,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Methylation at R550 (Pr = 0.10 | P = 0.04), ELME000155|PS00005,-
COL2A1_HUMAN,V575I,0.089,-,-,-
COL2A1_HUMAN,A580T,0.169,-,-,-
COL2A1_HUMAN,N611S,0.315,-,-,-
COL2A1_HUMAN,P646K,0.816,Gain of Methylation at P646 (Pr = 0.45 | P = 1.9e-05); Gain of Acetylation at P646 (Pr = 0.35 | P = 1.9e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at P646 (Pr = 0.25 | P = 8.4e-03); Gain of Ubiquitylation at P646 (Pr = 0.25 | P = 1.7e-03), ELME000155,-
COL2A1_HUMAN,A647T,0.169,-,-,-
COL2A1_HUMAN,P680Q,0.335,-,-,-
COL2A1_HUMAN,P686S,0.720,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of O-linked glycosylation at P686 (Pr = 0.14 | P = 0.03), ELME000085|ELME000156,-
COL2A1_HUMAN,T727N,0.434,-,-,-
COL2A1_HUMAN,P730S,0.698,Loss of Methylation at K731 (Pr = 0.25 | P = 1.8e-03); Gain of Acetylation at K731 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K731 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K731 (Pr = 0.17 | P = 0.03); Loss of O-linked glycosylation at T727 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000053|PS00008,-
COL2A1_HUMAN,K731T,0.821,Loss of Methylation at K731 (Pr = 0.50 | P = 9.7e-05); Gain of Loop (Pr = 0.33 | P = 1.6e-03); Loss of Acetylation at K731 (Pr = 0.33 | P = 2.8e-03); Loss of SUMOylation at K731 (Pr = 0.24 | P = 0.01); Loss of Ubiquitylation at K731 (Pr = 0.21 | P = 5.0e-03); Loss of O-linked glycosylation at T727 (Pr = 0.12 | P = 0.05), ELME000053,-
COL2A1_HUMAN,S734P,0.376,-,-,-
COL2A1_HUMAN,P736A,0.479,-,-,-
COL2A1_HUMAN,P740T,0.344,-,-,-
COL2A1_HUMAN,V806A,0.160,-,-,-
COL2A1_HUMAN,V806I,0.085,-,-,-
COL2A1_HUMAN,P832S,0.642,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085|ELME000155|ELME000197,-
COL2A1_HUMAN,G834T,0.962,Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of O-linked glycosylation at G834 (Pr = 0.13 | P = 0.04), None,-
COL2A1_HUMAN,F835I,0.496,-,-,-
COL2A1_HUMAN,S869T,0.370,-,-,-
COL2A1_HUMAN,A871S,0.298,-,-,-
COL2A1_HUMAN,G915T,0.968,Loss of B-factor (Pr = 0.31 | P = 5.9e-03); Gain of Phosphorylation at G915 (Pr = 0.24 | P = 0.04); Gain of O-linked glycosylation at S910 (Pr = 0.13 | P = 0.04); Gain of GPI-anchor amidation at N911 (Pr = 0.02 | P = 0.02), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,P920H,0.554,Loss of B-factor (Pr = 0.34 | P = 1.7e-03); Loss of Methylation at K925 (Pr = 0.29 | P = 7.6e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K925 (Pr = 0.26 | P = 7.7e-03); Loss of SUMOylation at K925 (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at S923 (Pr = 0.16 | P = 0.03), ELME000239,-
COL2A1_HUMAN,D926E,0.288,-,-,-
COL2A1_HUMAN,P937A,0.284,-,-,-
COL2A1_HUMAN,P938A,0.328,-,-,-
COL2A1_HUMAN,E955D,0.190,-,-,-
COL2A1_HUMAN,E955L,0.455,-,-,-
COL2A1_HUMAN,S965A,0.214,-,-,-
COL2A1_HUMAN,A967P,0.132,-,-,-
COL2A1_HUMAN,A967S,0.090,-,-,-
COL2A1_HUMAN,A967V,0.109,-,-,-
COL2A1_HUMAN,E968D,0.047,-,-,-
COL2A1_HUMAN,S1039T,0.151,-,-,-
COL2A1_HUMAN,P1072S,0.364,-,-,-
COL2A1_HUMAN,S1100A,0.133,-,-,-
COL2A1_HUMAN,I1108M,0.127,-,-,-
COL2A1_HUMAN,Q1109A,0.232,-,-,-
COL2A1_HUMAN,S1148A,0.173,-,-,-
COL2A1_HUMAN,V1169I,0.101,-,-,-
COL2A1_HUMAN,N1204K,0.383,-,-,-
COL2A1_HUMAN,N1204T,0.395,-,-,-
COL2A1_HUMAN,P1228A,0.111,-,-,-
COL2A1_HUMAN,P1228G,0.283,-,-,-
COL2A1_HUMAN,A1244P,0.697,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Proteolytic cleavage at D1242 (Pr = 0.19 | P = 3.1e-03); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), None,-
COL2A1_HUMAN,H1290L,0.952,Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000233,-
COL2A1_HUMAN,E1292A,0.728,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000239,-
COL2A1_HUMAN,N1327S,0.262,-,-,-
COL2A1_HUMAN,A1329V,0.189,-,-,-
COL2A1_HUMAN,N1330T,0.213,-,-,-
COL2A1_HUMAN,K1344Q,0.391,-,-,-
COL2A1_HUMAN,I1347V,0.116,-,-,-
COL2A1_HUMAN,I1353M,0.466,-,-,-
COL2A1_HUMAN,D1364G,0.452,-,-,-
COL2A1_HUMAN,V1373I,0.168,-,-,-
COL2A1_HUMAN,A1404S,0.260,-,-,-
COL2A1_HUMAN,N1406H,0.527,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Methylation at K1408 (Pr = 0.14 | P = 0.02), ELME000313,-
